CTMX Annual Cash & Cash Equivalents
$17.17 M
-$176.48 M-91.13%
31 December 2023
Summary:
As of January 23, 2025, CTMX annual cash & cash equivalents is $17.17 million, with the most recent change of -$176.48 million (-91.13%) on December 31, 2023. During the last 3 years, it has fallen by -$174.69 million (-91.05%). CTMX annual cash & cash equivalents is now -93.06% below its all-time high of $247.58 million, reached on December 31, 2018.CTMX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CTMX Quarterly Cash And Cash Equivalents
$40.58 M
-$2.67 M-6.18%
30 September 2024
Summary:
As of January 23, 2025, CTMX quarterly cash and cash equivalents is $40.58 million, with the most recent change of -$2.67 million (-6.18%) on September 30, 2024. Over the past year, it has increased by +$14.55 million (+55.92%). CTMX quarterly cash and cash equivalents is now -87.69% below its all-time high of $329.67 million, reached on March 31, 2021.CTMX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CTMX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -91.1% | +55.9% |
| 3 y3 years | -91.0% | +55.9% |
| 5 y5 years | -93.1% | +55.9% |
CTMX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -91.7% | at low | -80.3% | +136.3% |
| 5 y | 5-year | -91.7% | at low | -87.7% | +136.3% |
| alltime | all time | -93.1% | +97.3% | -87.7% | +136.3% |
CytomX Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $40.58 M(-6.2%) |
| June 2024 | - | $43.25 M(+19.5%) |
| Mar 2024 | - | $36.19 M(+110.7%) |
| Dec 2023 | $17.17 M(-91.1%) | $17.17 M(-34.0%) |
| Sept 2023 | - | $26.02 M(-54.8%) |
| June 2023 | - | $57.54 M(+2.1%) |
| Mar 2023 | - | $56.36 M(-70.9%) |
| Dec 2022 | $193.65 M(-5.8%) | $193.65 M(+103.8%) |
| Sept 2022 | - | $95.04 M(-26.5%) |
| June 2022 | - | $129.29 M(-20.9%) |
| Mar 2022 | - | $163.49 M(-20.5%) |
| Dec 2021 | $205.53 M(+7.1%) | $205.53 M(-13.0%) |
| Sept 2021 | - | $236.28 M(-7.8%) |
| June 2021 | - | $256.15 M(-22.3%) |
| Mar 2021 | - | $329.67 M(+71.8%) |
| Dec 2020 | $191.86 M(+1.8%) | $191.86 M(+8.5%) |
| Sept 2020 | - | $176.81 M(-39.3%) |
| June 2020 | - | $291.39 M(+103.4%) |
| Mar 2020 | - | $143.29 M(-24.0%) |
| Dec 2019 | $188.43 M | $188.43 M(+14.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2019 | - | $164.65 M(+10.2%) |
| June 2019 | - | $149.39 M(-21.5%) |
| Mar 2019 | - | $190.41 M(-23.1%) |
| Dec 2018 | $247.58 M(+39.4%) | $247.58 M(-4.7%) |
| Sept 2018 | - | $259.75 M(+95.4%) |
| June 2018 | - | $132.91 M(-6.5%) |
| Mar 2018 | - | $142.16 M(-19.9%) |
| Dec 2017 | $177.55 M(+69.7%) | $177.55 M(-37.5%) |
| Sept 2017 | - | $284.23 M(+4.2%) |
| June 2017 | - | $272.86 M(+218.5%) |
| Mar 2017 | - | $85.66 M(-18.1%) |
| Dec 2016 | $104.64 M(+74.9%) | $104.64 M(+75.1%) |
| Sept 2016 | - | $59.76 M(-4.2%) |
| June 2016 | - | $62.38 M(-8.1%) |
| Mar 2016 | - | $67.90 M(+13.5%) |
| Dec 2015 | $59.82 M(-7.1%) | $59.82 M(+65.3%) |
| Sept 2015 | - | $36.19 M(-21.1%) |
| June 2015 | - | $45.84 M(-28.8%) |
| Dec 2014 | $64.40 M(+639.9%) | $64.40 M |
| Dec 2013 | $8.70 M | - |
FAQ
- What is CytomX Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for CytomX Therapeutics?
- What is CytomX Therapeutics annual cash & cash equivalents year-on-year change?
- What is CytomX Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for CytomX Therapeutics?
- What is CytomX Therapeutics quarterly cash and cash equivalents year-on-year change?
What is CytomX Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CTMX is $17.17 M
What is the all time high annual cash & cash equivalents for CytomX Therapeutics?
CytomX Therapeutics all-time high annual cash & cash equivalents is $247.58 M
What is CytomX Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, CTMX annual cash & cash equivalents has changed by -$176.48 M (-91.13%)
What is CytomX Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CTMX is $40.58 M
What is the all time high quarterly cash and cash equivalents for CytomX Therapeutics?
CytomX Therapeutics all-time high quarterly cash and cash equivalents is $329.67 M
What is CytomX Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, CTMX quarterly cash and cash equivalents has changed by +$14.55 M (+55.92%)